The clinical significance of an autoimmune response against glutamic acid decarboxylase
- 1 February 1996
- journal article
- review article
- Published by Springer Nature in Nature Medicine
- Vol. 2 (2) , 148-153
- https://doi.org/10.1038/nm0296-148
Abstract
Glutamic acid decarboxylase is attracting much interest because of its putative involvement in two clinical disorders: stiffman syndrome and insulin-dependent diabetes. Here we discuss the clinical significance of an autoimmune response against GAD and consider how such information may help identify the disease mechanisms of these disorders.Keywords
This publication has 29 references indexed in Scilit:
- The Pathogenesis of Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1994
- Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitusThe Lancet, 1994
- Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of diseaseThe Lancet, 1994
- Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetesThe Lancet, 1993
- Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetesThe Lancet, 1992
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990
- 64 000 Mr autoantibodies as predictors of insulin-dependent diabetesThe Lancet, 1990
- Autoantibodies to GABA-ergic Neurons and Pancreatic Beta Cells in Stiff-Man SyndromeNew England Journal of Medicine, 1990
- Stiff-Man Syndrome — An Autoimmune Disease?New England Journal of Medicine, 1988
- Autoantibodies to Glutamic Acid Decarboxylase in a Patient with Stiff-Man Syndrome, Epilepsy, and Type I Diabetes MellitusNew England Journal of Medicine, 1988